AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III Head-to-Head ELEVATE-RR Trial for Chronic Lymphocytic Leukemia

 AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III Head-to-Head ELEVATE-RR Trial for Chronic Lymphocytic Leukemia

Shots:

  • The P-III head-to-head ELEVATE-RR trial evaluating Calquence (100mg, PO, bid) vs ibrutinib (420mg, PO, qd) in a ratio (1:1) in 533 patients with previously treated CLL
  • The trial met its 1EPs i.e PFS non-inferiority with an m-PFS of 38.4 mos. @median follow up (40.9mos.). The 2EPs include lower incidence of all-grade atrial fibrillation (9.4% vs 16.0%), safety and tolerability were consistent with the known profile of Calquence, mOS was not reached
  • Additionally, P-III ELEVATE-TN trial showed strong PFS benefit of therapy as combination or as monothx. and favorable tolerability through 4 yrs. The results of both trials were presented at ASCO2021

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Mint

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post